- Home
- BOLD
as 05-20-2024 4:00pm EST
$.
+$.
+.%
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 221.7M | IPO Year: | 2024 |
| Target Price: | $23.00 | AVG Volume (30 days): | 201.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.39 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.51 - $15.24 | Next Earning Date: | 05-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Share on Social Networks:
Stock Insider Trading Activity of Boundless Bio Inc. Common Stock (BOLD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| CRANDELL KEITH | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 133,333 | $2,133,328.00 | 1,181,766 | SEC Form 4 |
| CRANDELL KEITH | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 66,667 | $1,066,672.00 | 683,759 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 296,875 | $4,750,000.00 | 1,884,787 | SEC Form 4 |
| RA CAPITAL MANAGEMENT, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 15,625 | $250,000.00 | 295,844 | SEC Form 4 |
| ARCH Venture Fund IX, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 66,667 | $1,066,672.00 | 683,759 | SEC Form 4 |
| ARCH Venture Fund IX, L.P. | BOLD | 10% Owner | Apr 2 '24 | Buy | $16.00 | 133,333 | $2,133,328.00 | 1,181,766 | SEC Form 4 |
| Burow Kristina | BOLD | Director10% Owner | Apr 2 '24 | Buy | $16.00 | 66,667 | $1,066,672.00 | 683,759 | SEC Form 4 |
| Burow Kristina | BOLD | Director10% Owner | Apr 2 '24 | Buy | $16.00 | 133,333 | $2,133,328.00 | 1,181,766 | SEC Form 4 |
Latest Boundless Bio Inc. Common Stock News
BOLD Breaking Stock News: Dive into BOLD Ticker-Specific Updates for Smart Investing
Business Wire
7 days ago
Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights
Business Wire
14 days ago
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
Business Wire
a month ago
Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications
Business Wire
a month ago